JP2004503246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004503246A5 JP2004503246A5 JP2002510700A JP2002510700A JP2004503246A5 JP 2004503246 A5 JP2004503246 A5 JP 2004503246A5 JP 2002510700 A JP2002510700 A JP 2002510700A JP 2002510700 A JP2002510700 A JP 2002510700A JP 2004503246 A5 JP2004503246 A5 JP 2004503246A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense compound
- antisense
- ebpα
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/593,589 US6306655B1 (en) | 2000-06-13 | 2000-06-13 | Antisense inhibition of C/EBP alpha expression |
| PCT/US2001/018803 WO2001096586A1 (en) | 2000-06-13 | 2001-06-11 | Antisense modulation of c/ebp alpha expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004503246A JP2004503246A (ja) | 2004-02-05 |
| JP2004503246A5 true JP2004503246A5 (enExample) | 2005-02-03 |
Family
ID=24375326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002510700A Withdrawn JP2004503246A (ja) | 2000-06-13 | 2001-06-11 | Ｃ／ＥＢＰα発現のアンチセンスモジュレーション |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6306655B1 (enExample) |
| EP (1) | EP1290204A1 (enExample) |
| JP (1) | JP2004503246A (enExample) |
| AU (1) | AU2001268322A1 (enExample) |
| WO (1) | WO2001096586A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| SI2336318T1 (sl) * | 2002-11-13 | 2013-07-31 | Genzyme Corporation | Protismiselna modulacija ekspresije apolipoproteina B |
| AU2008230886B9 (en) | 2007-03-24 | 2014-09-04 | Kastle Therapeutics, Llc | Administering antisense oligonucleotides complementary to human apolipoprotein B |
| WO2012142480A1 (en) * | 2011-04-14 | 2012-10-18 | Beth Israel Deaconess Medical Center, Inc. | Chimeric rna oligonucleotides and uses thereof |
| EP4060043A1 (en) | 2011-06-21 | 2022-09-21 | MiNA Therapeutics Limited | Albumin production and cell proliferation |
| JP7525578B2 (ja) * | 2013-11-22 | 2024-07-30 | ミナ セラピューティクス リミテッド | Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物 |
| EP3985118A1 (en) | 2013-11-22 | 2022-04-20 | MiNA Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545563A (en) | 1993-03-04 | 1996-08-13 | Baylor College Of Medicine | Human C/EBP gene and vectors for its expression |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2000
- 2000-06-13 US US09/593,589 patent/US6306655B1/en not_active Expired - Lifetime
-
2001
- 2001-06-11 EP EP01946246A patent/EP1290204A1/en not_active Withdrawn
- 2001-06-11 JP JP2002510700A patent/JP2004503246A/ja not_active Withdrawn
- 2001-06-11 AU AU2001268322A patent/AU2001268322A1/en not_active Abandoned
- 2001-06-11 WO PCT/US2001/018803 patent/WO2001096586A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513626A5 (enExample) | ||
| JP2004509619A5 (enExample) | ||
| CA2397590A1 (en) | Antisense inhibition of ptp1b expression | |
| JP2005520489A5 (enExample) | ||
| JP2003523739A5 (enExample) | ||
| JP2018150344A5 (enExample) | ||
| JP2009508527A5 (enExample) | ||
| CA2451643A1 (en) | Antisense modulation of superoxide dismutase 1, soluble expression | |
| JP2010505432A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2004535179A5 (enExample) | ||
| JP2016530882A5 (enExample) | ||
| US12104154B2 (en) | Antisense oligonucleic acid | |
| JP2004503232A5 (enExample) | ||
| JP2018184423A5 (enExample) | ||
| CA2343102A1 (en) | Antisense modulation of survivin expression | |
| JP2005504522A5 (enExample) | ||
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP2007505627A5 (enExample) | ||
| JP2019534009A5 (enExample) | ||
| JP2006141402A5 (enExample) | ||
| JP2004503246A5 (enExample) | ||
| WO2021153747A1 (ja) | Ａｔｎ１のアンチセンスオリゴヌクレオチド | |
| EP1531834A1 (en) | Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders | |
| CN112534055A (zh) | 用于调节rtel1表达的寡核苷酸 |